|
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Exogenously introduced wild-type and mutant p53 have recently been reported to enhance the human epidermal growth factor receptor (EGF-R) gene promoter activity in p53-deficient Saos2 osteosarcoma cells.
|
9285564 |
1997 |
|
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
EGFR expression was detected in the majority of osteosarcoma tumors surveyed (23 of 28; 82%).
|
18704985 |
2008 |
|
Osteosarcoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Six of 12 (50%) osteosarcoma cell lines revealed moderate to high expression levels of EGFR.
|
17509661 |
2007 |
|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Preclinical studies using human OS xenografts revealed that only tumors expressing both EGFR and c-Fos responded to anti-EGFR therapy demonstrating that c-Fos can be considered as a novel biomarker predicting response to anti-EGFR treatment in OS patients.
|
30361264 |
2018 |
|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The new virus displayed a highly selective targeting profile, with reduced infection of EGFR-negative cells and efficient killing of EGFR-positive cancer cells including primary EGFR-positive osteosarcoma cells that are refractory to infection by conventional adenoviruses.
|
17184803 |
2007 |
|
Osteosarcoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
EGFR expression was detected in the majority of osteosarcoma tumors surveyed (23 of 28; 82%).
|
18704985 |
2008 |
|
Osteosarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The TFs identified in the EGFR promoter may function in the progression of OS.
|
29435005 |
2018 |
|
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry on primary tumor samples and FACS analysis on primary short-term cultures and four OS cell lines showed that EGFR was consistently expressed.
|
12221644 |
2003 |
|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Functionality of EGFR in osteosarcoma cells was proven by EGF-mediated activation of both MAPK and PI3K/AKT pathway (determined by phosphorylation of ERK1/2, AKT, S6, and GSK3β).
|
26526352 |
2015 |
|
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
15-Deoxy-Δ12,14-prostaglandin J2 induces Cox-2 expression in human osteosarcoma cells through MAPK and EGFR activation involving reactive oxygen species.
|
21236332 |
2011 |
|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We hereby constructed sali-entrapped lipid-polymer nanoparticles labeled with CD133 and EGFR aptamers (CESP) to target both osteosarcoma cells and CSCs.
|
29898423 |
2018 |
|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As the sensitivity of only a few tumors to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) can be explained by the presence of EGFR tyrosine kinase (TK) domain mutations, there is a need to elucidate mechanisms of resistance to EGFR-targeted therapies in OS that do not harbor TK sensitizing mutations to develop new strategies to circumvent resistance to EGFR inhibitors.
|
31138318 |
2019 |
|
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We conclude that the cell surface expression of Her-2 and EGFR and the nuclear localization of the activated p80 fragment of Her-4 suggest that all three may be contributing to osteosarcoma pathogenesis.
|
15026342 |
2004 |
|
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Ninety-one of 111 (81%) of osteosarcomas revealed an expression of EGFR.
|
17505002 |
2007 |
|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study describes further investigations into the role of ERs in mediating the effects induced by E(2) and SERMs on EGFR expression, and the relationship between the actions of ERs and EGFR in U2OS osteosarcoma cells stably expressing ERalpha or ERbeta.
|
19347870 |
2009 |
|
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Xenografted SPC24 knockdown osteosarcoma cells showed reduced tumor growth in nude mice with decreased EGFR and phospho-ERK levels and increased E-cadherin levels.
|
29285250 |
2017 |
|
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Unlike EGFR or PDGFR, IGF1Rβ levels correlated with CYR61 and N-cadherin levels, and with the aggressiveness of osteosarcoma and overall survival.
|
30642298 |
2019 |
|
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Two out of three osteosarcoma cell lines showed increased EGFR levels as detected by real-time PCR.
|
19212684 |
2009 |
|
Osteosarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Six of 12 (50%) osteosarcoma cell lines revealed moderate to high expression levels of EGFR.
|
17509661 |
2007 |
|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, we investigated the effects of sodium cantharidate (SC), either as monotherapy and in combination with the EGFR inhibitor erlotinib, on STAT3 activation and osteosarcoma cell growth.
|
31422383 |
2019 |
|
Osteosarcoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Met interacts with EGFR and Ron in canine osteosarcoma.
|
22235915 |
2013 |